UroGen Pharma (URGN) Receivables - Net (2016 - 2026)

UroGen Pharma (URGN) has reported Receivables - Net for 9 consecutive years, with $55.4 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Net rose 182.17% year-over-year to $55.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.4 million (up 182.17% YoY) and the FY2025 annual result came in at $33.1 million, up 62.95% from the prior year.
• Receivables - Net rose to $55.4 million in Q1 2026 per URGN's latest filing, from $33.1 million in the prior quarter.
• Over the last five years, Receivables - Net for URGN reached as high as $55.4 million in Q1 2026 and fell as low as $9.4 million in Q3 2022.
• A 5-year average of $18.9 million and a median of $15.5 million in 2023 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2025 — Receivables - Net declined 13.59% — and 2026, when it soared 182.17%.
• Year by year, Receivables - Net stood at $12.7 million in 2022, then increased by 21.56% to $15.4 million in 2023, then jumped by 31.46% to $20.3 million in 2024, then surged by 62.95% to $33.1 million in 2025, then soared by 67.5% to $55.4 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $55.4 million, $33.1 million, and $19.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.